چكيده به لاتين
The main goal of targeted drug delivery is to help treat patients through the development of common drug therapy methods. During the last few decades, drug delivery technology has made significant progress, which leads to the development of various clinical formulations, improving patient compatibility and comfort. Targeted drug delivery means transferring the drug loaded in a target carrier to the target tissue. This system has many advantages, the most important of which are the ability to maintain the drug concentration at a relatively constant level for a certain period of time, the ability to adjust the drug release rate depending on the drug delivery site, the ability to deliver the drug to a specific organ or tissue, the ability to deliver several medicinal substances at the same time. With a formulation, it is possible to deliver drugs in nanometer dimensions, etc. In fact, targeted drug delivery refers to the accumulation of the drug in the desired area, which is independent of the way the drug is administered. In this project, pluronic hydrogel F127 was used as the main carrier for the delivery of chemotherapy drug doxorubicin to glioblastoma brain tumor. On the other hand, trimethylchitosan compound was synthesized to change the conditions and adjust the drug release profile and was added to the main carrier, and infrared and nuclear magnetic resonance spectrometer analyzes were used to confirm its synthesis. After determining the optimal concentration of Pluronic (15% w/w) and trimethylchitosan (0.03% w/w) using rheology analysis, the morphology of the final composition was analyzed using scanning electron microscopy, which resulted in the creation of more distinct micelles. and cavity formation was in the presence of trimethyl chitosan. After confirming the structure of the hydrogel, the drug was loaded into the carrier and dynamic light scattering analysis was used to confirm the loading. In the absence of the drug, the average particle size was 49.6€ and in the presence of the drug, the average particle size was 74.6, which indicated the loading of the drug in the micelles. After the final preparation of the hydrogel, in order to check and measure the drug release with the dialysis technique, an ultraviolet-visible spectroscopic device was used at a wavelength of 480 nm, and the drug release was investigated at pH 7.4 and 5.5. took which showed that in (pH=5.5) after 24 hours from the initial time, 54% of the drug was released and the rest was released slowly and continuously during 11 days, and after 12 days, almost all of the drug was released. Loaded in the environment with phosphate was released, and on the other hand, in the environment with (pH=7.4), the drug release rate is lower than in the acidic environment, so that during the first 24 hours, about 20% of the drug was released, and this shows It is a controlled release agent of doxorubicin in acidic medium compared to neutral medium. Finally, in order to investigate the effect of the carrier and the drug loaded in it on C6 glioblastoma brain tumors, cytotoxicity analysis was performed by the MTT method, as a result of which Pluronic/TMC hydrogels showed little toxicity on C6 cells during two treatment times, 24 and They had 48 hours and with the increase in the concentration of doxorubicin, the percentage of cell viability also decreases.
